CLARITHROMYCIN TO PREVENT SECONDARY INFECTIONS IN PATIENTS WITH SEPSIS FOLLOWING LOWER RESPIRATORY TRACT INFECTIONS: THE CLASSIFY TRIAL
A legfontosabb adatok
- Ki végzi
- Hellenic Institute for the Study of Sepsis
- Hol
- Görögország15 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Fázis
- 3. fázis
- Résztvevők
- 252 fő, tervezett
- Kezdés
- 2026. szept. 16.
- Várható befejezés
- 2029. dec.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Placebo
- clarithromycin
- A regiszteradat frissítve
- 2026. november 3.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 28 feltétel megnézéseKevesebb
Ki vehet részt
- Age equal to or above 18 years
- Patients of either gender
- Written informed consent provided by the patient. For patients without decision-making capacity, informed consent must be obtained from a legally designated representative following the national legislation
- Negative (blood or urinary) pregnancy test for female patients of reproductive age
- For female patients of reproductive age, willingness to use highly effective contraception during and seven days after the administration of the IMP
- Presence of Community-acquired pneumonia (CAP)
- Presence of sepsis as defined by the Sepsis-3 classification criteria (at least 2 points increase of the total SOFA-1 score from the baseline score of the specific patient). The SOFA score which will be used for the definition of sepsis has recently been renamed SOFA-1
- Absolute lymphocyte count (ALC) less than 1000/mm³
Ki nem vehet részt
- Unwillingness to receive contraception during and seven days after the administration of the IMPstudy drug (for Female patients)
- Solid organ or bone marrow transplantation
- Corticosteroid oral or intravenous intake greater than 0.4mg/kg of equivalent prednisone daily over the last 15 days or other immunosuppressive therapy. However, corticosteroids received as adjunctive treatment for the current septic/infectious episode are allowed
- Previous participation in the CLASSIFY study
- Known active neoplasms or other conditions unrelated to sepsis that compromise short-term survival less than 6 months
- Medical history of allergy to macrolides
- Medical history of torsades de pointes arrhythmia
- Severe hepatic failure in combination with renal impairment
- Known HIV infection with known CD4 cell count <200/mm³
- QTc interval at rest in the ECG ≥500 msec or history of known long QT syndrome
- Concomitant use of medicinal products contraindicated with clarithromycin, including CYP3A substrates associated with QT prolongation (e.g., astemizole, cisapride, domperidone, pimozide, terfenadine, ivabradine), ergot alkaloids (e.g., ergotamine, dihydroergotamine), oral midazolam, HMG-CoA reductase inhibitors primarily metabolised by CYP3A4 (e.g., lovastatin, simvastatin), colchicine, ticagrelor, and ranolazine. This criterion applies to all medicinal products within these classes, not only the specific examples listed, in accordance with the SmPC for clarithromycin. Patients may be enrolled provided that such medications are discontinued prior to or at the time of trial participation. Given their short half-life, no wash-out period is required
- Age below 18 years
- Denial of written informed consent
- Pregnancy (confirmed by blood or urinary pregnancy test) or lactation for female patients
- Intake of a biological agent in the last month
- Neutropenia < 500/mm³
- Intake of any macrolide for the current episode of CAP under study
- Severe hypokalemia or hypomagnesemia; patients may be enrolled once these electrolyte abnormalities are corrected
- Any contradictions for macrolide uptake
- Participation in any other interventional trial within the last 30 days
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
The goal of this clinical trial is to assess whether clarithromycin, given as an adjunct to standard-of-care antibiotic therapy, can reduce the risk of new infections and secondary sepsis in adult patients hospitalized with community-acquired pneumonia (CAP), sepsis, and sepsis-induced immunoparalysis (SII). The primary objective is to evaluate the effect of clarithromycin on the incidence of new infection, including worsening or recurrence of the initial CAP episode, new infections at other sites, and secondary sepsis during the 28-day follow-up period. Secondary objectives are to investigate the impact of clarithromycin on mortality, sepsis response, type of secondary infection, time to antimicrobial escalation, hospital readmission, quality of life, cost-effectiveness, and biomarkers of sepsis-induced immunoparalysis.
A teljes eredeti leírásKevesebb
Researchers will compare clarithromycin plus standard-of-care antibiotic therapy to placebo plus standard-of-care antibiotic therapy.
Participants will:
* Receive clarithromycin or placebo, administered orally or intravenously, in addition to standard-of-care antibiotic therapy for up to 7 days. * Be evaluated during treatment and follow-up through Day 28, with additional assessment of mortality, hospital readmission, and health status through Day 90.
A vizsgálat 2 csoportja
- Standard-of-care (SoC) and placeboPlacebo, összehasonlításként
In the case of IV placebo medication, patients receive water for injection at a volume of 10ml diluted to a final volume of 250 ml dextrose in water 5%. The duration of the infusion is 1 hour and treatment is given every 12 hours daily for 7 days. In the case of oral placebo medication, this is given as oral tablets every 12 hours once for 7 days. Step-down from IV to oral medication, respectively, is permitted.
Kezelés: Placebo
- Standard-of-care (SoC) and clarithromycinMár használt kezelés, összehasonlításként
In the case of IV medication, patients receive 500 mg of clarithromycin diluted with water for injection at a volume of 10ml and further diluted to a final volume of 250 ml dextrose in water 5%. The duration of the infusion is 1 hour and treatment is given every 12 hours daily for 7 days. In the case of oral medication, this is given as clarithromycin IR 500mg every 12 hours for 7 days. Step-down from IV to oral medication, respectively, is permitted.
Kezelés: clarithromycin
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- A regiszteradat frissítve
- 2026. november 3.